Journal
CANCER LETTERS
Volume 399, Issue -, Pages 44-52Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.04.013
Keywords
Chimeric antigen receptor; Bispecific antibody; Hepatocellular carcinoma; Treatment
Categories
Funding
- Enid A. Haupt Endowed Chair
- Kids Walk for Kids with Cancer NYC
- Katie Find a Cure Foundation
- Robert Steel Foundation
- NIH/NCI Cancer Center [P30 CA008748]
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall survival rate of less than 15% in developed countries. Despite attempts at new therapeutic strategies, the majority of patients succumb to this cancer. Buttressed by the highly successful clinical impact in melanoma, immunotherapy is gaining momentum as the next treatment modality for many human cancers. Chimeric antigen receptors (CAR) contain the antigen binding moieties of a monoclonal antibody and the co-stimulatory and signaling domains associated with effector receptor signaling. Bispecific antibodies (BsAb) combine the binding specificities of two different monoclonal antibodies, one activating a receptor on a killer effector cell, while the other, engaging a tumor-associated antigen to initiate tumor cytotoxicity. In this review, we survey the HCC targets for which CARs and bispecific antibodies have been generated. The pros and cons of these targets for T-cell and Natural Killer cell based immunotherapy will be discussed. Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available